Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

Advice Statement

  • Home
  • Our Advice
  • PET-CT in investigating and or assessing patients for diagnosis and or staging of myeloma

Title

Output Type

Speciality

Published

Title

PET-CT in investigating and or assessing patients for diagnosis and or staging of myeloma

Output Type

Advice Statement

Speciality

Cancer, Blood and immune system

Published

4 May 2018

Recommendation for NHSScotland

The evidence for diagnostic accuracy of PET/CT consists of limited clinical effectiveness evidence and PET/CT was also found not to be cost-effective for the diagnosis of myeloma across a wide range of possible sensitivity and specificity values (60-100%).

For disease staging in newly diagnosed myeloma patients, PET/CT detects a greater number of lesions than plain film radiography (x-ray) but there is insufficient evidence to determine if it can detect more lesions than MRI.

The current evidence suggests that PET/CT should not be routinely considered in the diagnosis and staging of myeloma.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

What were we asked to look at?

We were asked to provide advice on the use of positron emission tomography/computed tomography (PET/CT) in investigating and/or assessing patients for diagnosis and/or staging of myeloma.

Why is this important?

Guidelines on imaging technologies for myeloma have recently been reviewed. New information about the effectiveness of FDG PET/CT could see this being used more widely. By evaluating clinical situations where PET/CT could prove most effective, patients and the NHS can both benefit from investment in these machines.

Referred by

Scottish Clinical Imaging Network PET/CT Group

 

Download icon
Download Advice
pdf (268 KB)
Download icon
Download Plain Language Summary
pdf (344 KB)
Download icon
Download Evidence Note
pdf (912 KB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 31 January 2022

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?